

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 3, 2021

**APOLLO MEDICAL HOLDINGS, INC.**  
(Exact Name of Registrant as Specified in Charter)

Delaware  
(State or Other Jurisdiction  
of Incorporation)

001-37392  
(Commission  
File Number)

95-4472349  
(I.R.S. Employer  
Identification No.)

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801  
(Address of Principal Executive Offices) (Zip Code)

(626) 282-0288  
Registrant's Telephone Number, Including Area Code

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	AMEH	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 8.01 Other Events**

On November 3, 2021, Apollo Medical Holdings, Inc. (together with its subsidiaries and affiliated entities, the “Company”) announced that the Company has, through various subsidiaries and affiliates, entered into an agreement to purchase within three years all of the remaining equity interests in Diagnostic Medical Group of Southern California (“DMG”). The Company's affiliate currently owns 40% of DMG and has committed to purchasing the remaining 60% within three years.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Press Release of Apollo Medical Holdings, Inc., dated November 3, 2021</a>
104	Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**APOLLO MEDICAL HOLDINGS, INC.**

Date: November 3, 2021

By: /s/ Thomas S. Lam  
Name: Thomas S. Lam, M.D., M.P.H.  
Title: Co-Chief Executive Officer and President



**Apollo Medical Holdings, Inc. Announces Signing of Agreement to Purchase the Remaining 60% of Equity Interests of Diagnostic Medical Group of Southern California Within Three Years**

ALHAMBRA, Calif., November 3, 2021 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that the Company's affiliate has entered into an agreement to purchase within three years all of the remaining equity interests in Diagnostic Medical Group of Southern California ("DMG"). The Company's affiliate currently owns 40% of DMG and has committed to purchasing the remaining 60% within three years. In accordance with relevant accounting guidance, the Company has determined that DMG is a variable interest entity of the Company, and therefore, DMG's financial statements will be consolidated with those of the Company consistent with U.S. generally accepted accounting principles.

DMG is a complete outpatient imaging center providing MRI, CT, x-ray, bone density, nuclear medicine, ultrasound and mammogram exams, among others. DMG has been serving patients in the community since 1984 and currently operates four locations in the San Gabriel Valley area of southern California.

As the Company makes progress on its growth strategy, it expects to leverage its extensive network advantages and operational experience in introducing DMG to new markets in other geographic regions.

Kenneth Sim, M.D., Executive Chairman and Co-Chief Executive Officer of ApolloMed, stated, "We look forward to working more closely with the team at DMG going forward with a goal of continuing to support the superior quality of DMG's patient experience for which it is already recognized within the communities it serves. We are thrilled to add DMG to ApolloMed's extensive network of service offerings for our affiliated physicians and members and believe there is an opportunity to bring DMG's diagnostic exam services to other geographic regions as our Company grows."

David Chen, M.D., President of DMG, added, "DMG is pleased to expand upon our existing relationship with ApolloMed, which has been a longtime valued partner of ours. DMG has been a trusted provider of various diagnostic services in the San Gabriel Valley since 1984, and we believe working more closely with ApolloMed will enhance our overall operational efficiencies, bringing greater benefits to the patient populations we serve."

**About Apollo Medical Holdings, Inc.**

ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that

---

enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.

Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and a Next Generation Accountable Care Organization (NGACO). For more information, please visit [www.apollomed.net](http://www.apollomed.net).

#### **Forward Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company's investment in, and arrangements with, DMG (including the Company's acquisition of additional equity interests in DMG and integration of DMG into the Company's network of service offerings), and ApolloMed's ability to deliver sustainable long-term value, ability to respond to the changing environment, operational focus, strategic growth and expansion plans, and future collaboration opportunities. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of ApolloMed's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in ApolloMed's reports filed with the Securities and Exchange Commission, including, without limitation, the risk factors contained in ApolloMed's Annual Report on Form 10-K for the year ended December 31, 2020, and any subsequent Quarterly Reports on Form 10-Q.

#### **FOR MORE INFORMATION, PLEASE CONTACT:**

Investor Relations

(626) 943-6491

[investors@apollomed.net](mailto:investors@apollomed.net)

Carolyne Sohn, The Equity Group

(415) 568-2255

[csohn@equityny.com](mailto:csohn@equityny.com)